Amphastar Pharmaceuticals' stock experienced a significant pre-market plunge of 14.68% on Friday, extending losses from the previous trading session.
The sharp decline follows the company's release of fourth-quarter financial results that fell short of analyst expectations. Amphastar reported adjusted earnings per share of $0.73, missing the consensus estimate of $0.92, while revenue of $183.11 million also came in below expectations.
Adding to the negative sentiment, Jefferies cut its price target on Amphastar Pharmaceuticals to $30 from $38. The combination of disappointing earnings performance and the analyst downgrade prompted the substantial sell-off in pre-market trading.
Comments